RSS

transdermal

Medherant — a company focused on transdermal drug delivery — has revealed that it has raised £3.8 million in its latest funding round, which will support the company as it progresses its ibuprofen TEPI Patch into clinical development early next year more

News

Medherant, developer of transdermal drug delivery patches, has been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards. more

Technology

Developer of next-generation transdermal drug delivery patches, Medherant, has signed an agreement with a Japanese transdermal patch company to evaluate the potential of the TEPI Patch technology. more

Technology

In this article Vasiliki Nikolaou and David M. Haddleton from Medherant, The Venture Centre University of Warwick Science Park, detail transdermal drug delivery, a non-invasive option that has the potential to improve patient adherence. more

, Opinion

Medherant, a University of Warwick spin-out company, developing transdermal drug delivery patch technology, has announced the appointment of Sheryl Caswell as head of clinical development. more

News

This study covers in detail the parenteral and transdermal excipients used in the pharmaceutical industry. more